UK Markets closed

Pfizer Inc. (PFE)

NYSE - NYSE Delayed price. Currency in USD
Add to watchlist
37.23+0.70 (+1.92%)
At close: 1:02PM EST
Full screen
Trade prices are not sourced from all markets
Previous close36.53
Open36.78
Bid37.24 x 1800
Ask37.29 x 1000
Day's range36.75 - 37.26
52-week range26.45 - 39.84
Volume25,080,500
Avg. volume33,594,268
Market cap206.939B
Beta (5Y monthly)0.64
PE ratio (TTM)24.21
EPS (TTM)1.54
Earnings date26 Jan 2021 - 01 Feb 2021
Forward dividend & yield1.52 (4.08%)
Ex-dividend date05 Nov 2020
1y target est41.78
  • The US could face an 'apocalypse’ by Christmas as COVID-19 cases surge: Dr.
    Editor's pick
    Yahoo Finance

    The US could face an 'apocalypse’ by Christmas as COVID-19 cases surge: Dr.

    As COVID-19 hospitalizations surpass 90,000 for the first time, a record for the seventeenth day in a row, Dr. Andre Campbell, a trauma surgeon at Zuckerberg San Francisco General Hospital, warns the U.S. could be facing an “apocalypse” next month. 

  • UK could become first Western country to approve a COVID-19 vaccine
    Yahoo Finance UK

    UK could become first Western country to approve a COVID-19 vaccine

    On Friday, the government wrote to the Medicines and Healthcare Products Regulatory Agency, asking it to review the Astrazeneca-Oxford University vaccine.

  • Pfizer's Vaccine Candidate Is Effective -- But It Has Issues
    Motley Fool

    Pfizer's Vaccine Candidate Is Effective -- But It Has Issues

    As the excitement over Pfizer (NYSE: PFE) and BioNTech's (NASDAQ: BNTX) vaccine announcement ebbs, some harsh realities have started to set in. The vaccine candidate -- while a marvelous feat of science -- has some hurdles to overcome if it's going to fulfill the promise of helping end the global pandemic. Let's look at a few issues the potential Pfizer vaccine will have to overcome to reward shareholders and save lives.